Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC's board rejects Pfizer's final proposal


Monday, 19 May 2014 02:08am EDT 

AstraZeneca PLC:Rejected final proposal from Pfizer Inc, comprising 24.76 pounds in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of 55.00 pounds per AstraZeneca share.Says this proposal undervalues the Company and its attractive prospects and has been rejected by the Board of AstraZeneca. 

Company Quote

68.28
-0.45 -0.65%
3 Mar 2015